WARF, Gregor join in prostate cancer study
Madison-based Gregor Diagnostics, a molecular diagnostics company, has entered into an exclusive license agreement with the Wisconsin Alumni Research Foundation around Gregor’s groundbreaking new screening test for prostate cancer.
According to a release, the agreement grants Gregor exclusive rights to intellectual property covering biomarkers that it anticipates developing and commercializing as part of a new screening test for the detection of prostate cancer from seminal fluid.
The biomarkers were discovered in the lab of Dr. David Jarrard at the UW Carbone Cancer Center.
Prostate cancer is the third leading cause of cancer death in American men.